Filter Your Results




FDA Clears External Craniostimulation Device for Treatment of Insomnia, Anxiety, and Depression

Thursday, March 28, 2019—The Food and Drug Administration (FDA) has cleared a novel cranial electrostimulation (CES) device (Cervella; Innovative Neurological Devices, Carmel, IN). Proprietary electro…

FDA Approves Solriamfetol for Treatment of Excessive Daytime Sleepiness

Thursday, March 21, 2019—The Food and Drug Administration (FDA) has approved solriamfetol (Sunosi; Jazz Pharmaceuticals, Dublin, Ireland) for the treatment of adults with excessive daytime sleepiness …

“Recovery Sleep” on Weekend Does Not Make Up for Lost Sleep During the Week

Monday, March 18, 2019—  Research published in Current Biologyshows that sleeping on the weekends to make up for lost sleep during the week has no beneficial effect for adults. In this …

New Drug Application Accepted for Lemborexant for Treatment of Insomnia

Tuesday, March 12, 2019—The Food and Drug Administration (FDA) accepted a New Drug Application (NDA) for lemborexant (Eisai, Woodcliff Lake, NJ). Lemborexant is novel small molecule being investigate…

Motor Function in Persons with REM Sleep Behavior Disorder Predictive of Conversion to Parkinson’s Disease

Tuesday, March 05, 2019—In a large multicenter study of 1,280 patients diagnosed with rapid eye movement (REM) sleep behavior disorder (RBD), published in Brain, patients’ scores on motor …

Pitolisant New Drug Application Granted Priority Review

Wednesday, February 13, 2019—Pitolisant (Harmony Biosciences; Plymouth Meeting, PA), an investigational drug being studied for the treatment of excessive daytime sleepiness and/or cataplexy in patients wi…

Tau Pathology of Alzheimer’s Linked to Sleep-Wake Cycle

Wednesday, February 06, 2019—Poor sleep is a symptom of Alzheimer’s disease (AD) that worsens as the disease progresses and is also suggested to be an early symptom of AD. It has been known for some…

Lemborexant Use Does Not Affect Next-Day Driving Performance

Thursday, January 24, 2019—In a phase 1 safety study, healthy adult volunteers, mean age 58.5 (age range 23-78 years), who took lemborexant (Eisai, Woodcliff Lake, NJ and Purdue, Stamford, CT) at b…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.